May 17, 2022 is the 18th “World Hypertension Day” in the world. The theme of this year’s World Hypertension Day is “Precise Measurement, Effective Control, Healthy Longevity” “. Taking this opportunity as “World Hypertension Day” is approaching, in order to further improve the compliance rate of blood pressure and blood lipid levels in my country; in order to further popularize the important role of antihypertensive and lipid-lowering therapy in preventing ASCVD events; Hanhui Pharmaceutical grandly held the “2022 Blood Pressure” In the “Blood Lipid Week” series of activities, a number of well-known domestic cardiovascular experts were invited to discuss the current situation of blood pressure and blood lipid management in my country, and look forward to the future development direction of comprehensive management. Beijing Anzhen Hospital Affiliated to Capital Medical UniversityProfessor Ma Changsheng, To analyze the occurrence and development of ASCVD, and to interpret the drug treatment strategies of combined antihypertensive and combined lipid-lowering.
Outpatient Clinic:< em>The National 14th Five-Year Plan and the 2035 Vision Outline both mention a healthy China, a strategy that requires people’s health to be prioritized for development Position, health prevention-oriented policy, in-depth implementation of Healthy China Action. What is the current status of blood pressure and blood lipid management in the prevention and management of atherosclerotic heart disease (ASCVD) in my country?
Professor Ma Changsheng:I am very pleased to be able to participate in the theme of the blood pressure and blood lipid week series of activities organized by Hanhui Pharmaceuticals. Activity. As we all know, my country’s medical conditions have been greatly improved in recent years, especially in first-tier cities, the awareness rate and compliance rate of basic diseases such as hypertension and dyslipidemia are rising rapidly. However, from the perspective of the overall population, combined with data from some underdeveloped areas and rural areas in my country, the current average awareness and compliance rates of hypertension and dyslipidemia in my country are far from sufficient. The compliance rate of hypertension in some developed countries is more than 50%, while in my country, only in some large cities and economically developed areas, the compliance rate of hypertension can reach about 30%, and there is still a certain gap between the developed countries; and small cities and rural areas. The figure is even smaller. In some cities, the hypertension compliance rate is in the tens of percent, and in rural areas it is even less than 10 percent. Not only in the management of hypertension, but also in the management of dyslipidemia. Therefore, in order to achieve the requirements for people’s health in the National 14th Five-Year Plan and the 2035 Vision and Objectives Outline, it is necessary to pay special attention to the management of important cardiovascular risk factors for ASCVD such as hypertension and dyslipidemia. one of the goals. It is hoped that through this activity, the awareness of Chinese residents on blood pressure and blood lipid management will be further improved, and the treatment strategies of clinicians in comprehensive management of blood pressure and blood lipids will be further standardized, so as to bring better prognosis to more patients.
Outpatient Clinic:< strong>Lowering blood pressure and lipids is a long-lasting core strategy in the management of ASCVD patients. How do Chinese guidelines treat and manage people at high risk of ASCVD? Why should a combination of antihypertensive and lipid-lowering drug treatment strategies be adopted for people at high risk of ASCVD and above? span>
Professor Ma Changsheng:Hypertension and dyslipidemia are both important risk factors for cardiovascular and cerebrovascular diseases. Control can significantly reduce the occurrence of cardiovascular and cerebrovascular events. The results of a number of large-scale clinical studies have also shown that comprehensive management of risk factors for cardiovascular and cerebrovascular diseases such as blood lipids and blood pressure at the same time will produce the effect of 1+1>2.
For hypertensive patients, combined antihypertensive treatment strategy is the basic method of antihypertensive treatment. To achieve target blood pressure levels, most hypertensive patients require a combination of two or more antihypertensive drugs. For patients with dyslipidemia, a number of evidence-based medical evidences show that the lower the LDL-C level, the better. Therefore, for the high-risk group of ASCVD, especially the majority of Chinese patients who are intolerant to statins, the combined anti-depressant therapy should be initiated as soon as possible. fat. Chinese guidelines also recommend that patients with high-risk ASCVD be initially treated with moderate-dose statins combined with cholesterol absorption inhibitors combined with lipid-lowering therapy, so that blood lipids can reach the target early and bring more clinical benefits to patients.
“2018 AHA/ACC Cholesterol Management Guidelines” and “2019 China Cholesterol Education Program Lipid-lowering Treatment and Expert Recommendations for Reducing Cardiovascular Events” both advocate that blood lipid management needs to be based on ASCVD risk Layered. For high-risk, very high-risk or ultra-high-risk ASCVD patients, or patients who have received the maximum tolerated dose of statins but have not yet reached the LDL-C target, combined non-statin therapy can be considered to improve the long-term LDL-C target rate and clinical efficacy . Some patients, such as familial hypercholesterolemia, often require a combination of multiple drugs to achieve long-term LDL-C targets. The domestic and foreign guidelines clarify the starting timing of non-statin therapy, and emphasize the evaluation and prediction of patients by clinicians, and the formulation of individualized treatment plans.
Nowadays, my country has many new technologies, new drugs, and new devices, and more and more non-statin drugs have entered our field of vision, such as my country’s first self-developed class of new drugs. The domestic cholesterol absorption inhibitor Haibo Maibu has been launched, with 100% clinical evidence of Chinese people, and it is more suitable for Chinese people to lower lipids. benefit and further reduce the incidence of cardiovascular and cerebrovascular events.
Outpatient Clinic:In recent years, the application of single-piece compound preparations recommended by domestic and foreign guidelines can bring better comprehensive treatment effect?
Professor Ma Changsheng:Blood pressure and blood lipid management are the most important issues in ASCVD prevention. Currently, the compliance rate of hypertension in my country is far from insufficient, and there is still a lot of room for improvement. Among them, the lack of application of single-piece compound preparations is one of the main reasons for the failure to increase the compliance rate of hypertension in my country. For patients, taking one drug, including two or even three antihypertensive drugs; Or taking one drug, which has both antihypertensive and lipid lowering effects, It will greatly help improve the patient’s treatment effect, and will also greatly improve the patient’s compliance. Therefore, at present, for general hypertensive patients, it is recommended to use a single-piece compound preparation. At the same time, we also hope to apply a single-piece compound preparation that combines blood pressure and lipid lowering to comprehensively manage a variety of ASCVD risk factors and further reduce the occurrence of cardiovascular events. The single-tablet compound preparation of amlodipine + atorvastatin, which can control blood pressure and also carry out lipid-lowering therapy, is advanced and important in concept, and is suitable for patients with hypertension and hyperlipidemia. Management is very helpful. We hope that through this series of activities of Hanhui’s “2022 Blood Pressure and Blood Lipid Week”, doctors can fully realize the therapeutic effect of single-tablet compound preparations such as amlodipine + atorvastatin at the conceptual level. It is impossible to achieve with pure antihypertensive or lipid-lowering therapy. Comprehensive management of blood pressure and blood lipids is of great significance in the prevention of cardiovascular and cerebrovascular events in high-risk ASCVD patients, which can benefit more patients.
The content of this article is original content of “Outpatient” magazine
Reprinted with permission and please indicate the source.
New Vision for Clinic Clinic span>｜WeChat: ClinicMZ
Long press, identify the QR code, and follow